About Us

MGVS develops unique cell-based therapies for large patient populations who suffer from cardiovascular and other vascular-related conditions and cannot be treated adequately with existing therapeutic modalities.

The company was established by Professors Moshe Flugelman and Basil Lewis in August 2000 in Lady Davis Carmel Medical Center, and had recently relocated to a new GMP facility in Nesher, Israel.

The company's two leading products, MultiGeneAngio and  MultiGeneGraft, have been approved by the FDA for clinical studies as treatment for peripheral arterial disease. We have recently completed enrollment and treatment of 12 patients in the first phase I/IIa study with MultiGeneAngio in collaboration with the  University of Michigan and  the University of Pennsylvania in the USA. Preliminary assessment demonstrated promising safety and clinical results. A second clinical study for a more severe stage of peripheral arterial disease is in progress in 5 leading medical centers in Israel.